Genetically determined ACE1/ACE2 mutual ratios can give back different susceptibilities and predispositions to SARS-CoV-2 progression and infection, responsible in part for different COVID-19 prognosis and mortality, and such information could be useful to pharmacogenetically combine the best drug-user matching and repositioning [2]. The gene discussed is ACE2; the disease is COVID-19.